UBER vs BOLT

For growth investors, Uber Technologies, Inc.

(UBER) is the stronger pick with 18. 3% revenue growth year-over-year, versus 0. 1% for Bolt Biotherapeutics, Inc. (BOLT). Uber Technologies, Inc. (UBER) offers the better valuation at 15. 5x trailing P/E (23. 5x forward), making it the more compelling value choice. Analysts rate Uber Technologies, Inc. (UBER) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Uber Technologies, Inc.

(UBER) delivered a total return of +42. 5%, compared to -99. 0% for Bolt Biotherapeutics, Inc. (BOLT). Over 10 years, the gap is even starker: UBER returned +90. 4% versus BOLT's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bolt Biotherapeutics, Inc.

(BOLT) is the lower-risk stock at 1. 01β versus Uber Technologies, Inc. 's 1. 09β — meaning UBER is approximately 7% more volatile than BOLT relative to the S&P 500. On balance sheet safety, Uber Technologies, Inc. (UBER) carries a lower debt/equity ratio of 48% versus 87% for Bolt Biotherapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Uber Technologies, Inc.

(UBER) is pulling ahead at 18. 3% versus 0. 1% for Bolt Biotherapeutics, Inc. (BOLT). On earnings-per-share growth, the picture is similar: Uber Technologies, Inc. grew EPS 3. 3% year-over-year, compared to -981. 8% for Bolt Biotherapeutics, Inc.. Over a 3-year CAGR, UBER leads at 17. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Uber Technologies, Inc.

(UBER) is the more profitable company, earning 19. 3% net margin versus -433. 7% for Bolt Biotherapeutics, Inc. — meaning it keeps 19. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UBER leads at 10. 7% versus -469. 3% for BOLT. At the gross margin level — before operating expenses — BOLT leads at 103. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BOLT: 44.

0% to $7. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Uber Technologies, Inc.

(UBER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09)). Both have compounded well over 10 years (UBER: +90. 4%, BOLT: -99. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (UBER (Technology) and BOLT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: UBER is a mid-cap high-growth stock; BOLT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.